Martha Gulati: Oral MHT Is Associated With Increased Thrombotic Risk
Martha Gulati, Director of the Davis Women Heart Center at Houston Methodist DeBakey Heart and Vascular Center, shared The BMJ‘s post on X:
“Consistent with prior research, oral MHT is associated with increased thrombotic risk.
The same is not seen with transdermal MHT.”
The BMJ (British Medical Journal) shared a post on X about a recent article by Julie Berggreen et al., adding:
“Compared with no use of hormone therapy, oral menopausal hormone therapy was associated with increased venous thromboembolic risk regardless of dosage and treatment duration, finds study.
No increased thrombotic risks were observed with transdermal therapy.”
Title: Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study
Authors: Julie Berggreen, Nelsan Pourhadi, Hannah Wood-Kurland, Ellen Løkkegaard, Christian Torp-Pedersen, Amani Meaidi

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines